A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

NCT00275262 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Disease
Lymphoma, Non-Hodgkin
Multiple Myeloma
Mantle Cell Lymphoma

Interventions

DRUG: Leuprolide acetate depot (LAD) 11.25 mg 3 Month
DRUG: Matched placebo

Sponsor

Abbott

Collaborators

[object Object]
[object Object]
[object Object]